Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: M.D. Anderson Cancer Center
Condition: CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
NCT03007030
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.